Clinical Features of Dopamine Agonist Withdrawal Syndrome in a Movement Disorders Clinic
JNNP 84:130-135, Pondal, M.,et al, 2013
The Nonmotor Problems of Parkinson's Disease
The Neurologist 6:18-27, Friedman,J.H.&Fernandez,H.H., 2000
Lesions of Basal Ganglia Due to Disulfiram Neurotoxicity
JNNP 55:925-929, Laplane,D.,et al, 1992
Disorders of the Autonomic Nervous System:Part 1. Pathophysiology & Clinical Features
Ann Neurol 21:419-430, McLeod,J.G.&Tuck,R.R., 1987
Neurological Disease In Ex-Far-East Prisoners Of War
Lancet 2:135-137, Gibberd,F.B.,et al, 1980
Neurologic Manifest. of Infective Endocarditis:A Review
Stroke 4:958, Greenlee,J.E.,et al, 1973
Neurologic Complications of Heroin Addiction
Bull NY Acad Sci 49:4, Ritcher,R.W.,et al, 1973
Neurologic Complications of Polycythemia
Ann Int Med 57:909, Silverstein,A.,et al, 1962
Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune
JAMA Neurol 80:673-681, Goldman,S.M.,et al, 2023
Vitamin B6 Deficiency Presenting with New-Onset Epilepsy and Status Epilepticus in a Patient with Parkinson Disease
Neurol 94:e2605-e2607, Modica, J.S.,et al, 2020
A 58-year-old Man with Hand Tremor and Episodes of Neck Pain
Neurol 93:557-561, Urso, D.,et al, 2019
Distinguishing Neuroimaging Features in Patients Presenting with Visual Hallucinations
AJNR 37:774-781, Winton-Brown, T.T.,et al, 2016
Parkinson Disease Subtypes
JAMA 71:499-504, Thenganatt, M. & Jankovic, J., 2014
Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
Patterns and Trends in Antipsychotic Prescribing for Parkinson Disease Psychosis
Arch Neurol 68:899-904, Weintraub, D.,et al, 2011
Neuropathy in Parkinson Disease
Neurol 77:1947-1950, e132, Rajabally, Y.A. and Martey, J., 2011
Dopamine Agonist Withdrawal Syndrome in Parkinson Disease
Arch Neurol 67:58-63, Rabinak,C. &Nirenberg,M., 2010
(-Synuclein Accumulation in Skin Nerve Fibers Revealed by Skin Biopsy in Pure Autonomic Failure
Neurol 74:608-610,536, Shishido,T.,et al, 2010
What Predicts Mortality in Parkinson Disease? A Prospective Population-Based Long-Term Study
Neurol 75:1270-1276, Forsaa,E.B.,et al, 2010
Sexual Function in Men and Women With Neurological Disorders
Lancet 369:512-525, Rees,P.M.,et al, 2007
Quetiapine for Agitation or Psychosis in Patients with Dementia and Parkinsonism
Neurol 68:1356-1363, Kurlan,R.,et al, 2007
Practice Parameter: Evaluation and Treatment of Depression, Psychosis, and Dementia in Parkinson Disease (An Evidence-Based Review)
Neurol 66:996-1002, Miyasaki,J.M.,et al, 2006
The Parkinsons Complex: Parkinsonism Is Just the Tip of the Iceberg
Ann Neurol 59:591-596, Langston,J.W., 2006
Pesticide Exposure and Risk for Parkinsons Disease
Ann Neurol 60:197-203, Ascherio,A.,et al, 2006
Autonomic Failure as the Initial Presentation of Parkinson Disease and Dementia with Lewy Bodies
Neurol 63:1093-1095, Kaufmann,H.,et al, 2004
Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)
Pract Neurology 4:50-55, Razvi,S.S.M. &Muir,K.W., 2004
Constipation in Neurological Diseases
JNNP 74:13-19, Winge,K.,et al, 2003
Ten Most Commonly Asked Questions About the Psychiatric Aspects of Parkinson's Disease
The Neurologist 9:50-56, Reich,S.G. & Marsh,L., 2003
Treatments of Parkinson Disease
Arch Neurol 60:1680-1684, Shults,C.W., 2003
MR Imaging Findings After Stereotactic Radiosurgery Using the Gamma Knife
AJR 176:1589-1595, Friedman,D.P.,et al, 2001
Quetiapine for L-Dopa-Induced Psychosis in PD
Neurol 54:1538, Weiner,W.J.,et al, 2000
Treatment of Drug-Induced Psychosis with Quetiapine and Clozapine in Parkinson's Disease
Neurol 55:1753-1754, Dewey,R.B.Jr. & O'Suilleabhain,P.E., 2000
Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
NEJM 340:757-763,801, The Parkinson Study Group, 1999
Prevalence and Clinical Correlates of Psychotic Symptoms in parkinson Disease
Arch Neurol 56:595-601, Aarsland,D.,et al, 1999
Transderm-induced Psychosis in Parkinson's Disease
Neurol 53:433-434, Minagar,A.,et al, 1999
Recent Advances, Neurology
BMJ 319:362-366, Larner,A.J.&Farmer,S.F., 1999
An Algorithm (Decision Tree) for the Management of Parkinson's Disease:Trtm Guidelines
Neurol 50:S1-S57, Olanow,C.W.&Koller,W.C., 1998
Acute Delirium After Withdrawal of Amantadine in Parkinson's Disease
Neurol 50:1456-1458, Factor,S.A.,et al, 1998
Managing the Neuropsychiatric Symptoms of Parkinson's Disease
Neurol 50:S33-S38, Lieberman,A., 1998
Olanzapine in the Treatment of Dopaminomimetic Psychosis in Patients with Parkinson's Disease
Neurol 50:1195-1196, Wolters,E.C.,et al, 1998
Early Dopaminergic Drug-Induced Hallucinations in Parkinsonian Patients
Neurol 51:811-814, Goetz,C.G.,et al, 1998
Sympathetic Cardioneuropathy in Dysautonomias
NEJM 336:696-702, 7211997., Goldstein,D.S.,et al, 1997
Occupational Exposures to Metals as Risk Factors for Parkinson's Disease
Neurol 48:650-658, Gorell,J.M.,et al, 1997
Managing the Late Complications of Parkinson's Disease
Neurol 49:549-557, Waters,C.H., 1997
Lewy Body Disease and Dementia
Arch Int Med 156:487-493, Kalra,S.,et al, 1996
Diffuse Lewy Body Disease:Clinical Features in Nine Cases without Coexistent Alzheimer's Disease
JNNP 60:531-538, Hely,M.A.,et al, 1996
Nonmotor Fluctuations in Patients with Parkinson's Disease
Neurol 47:1180-1183, Hillen,M.E.&Sage,J.I., 1996
Clinical and Pathological Features in Hydrocarbon-Induced Parkinsonism
Ann Neurol 40:922-925, Pezzoli,G.,et al, 1996